Median Technologies (DE:4ZG)
FRANKFURT:4ZG
Want to see DE:4ZG full AI Analyst Report?
4ZG Stock Chart & Stats
€3.22
€0.01(0.25%)
At close: 4:00 PM EST
€3.22
€0.01(0.25%)
Day’s Range― - ―
52-Week Range€1.24 - €6.42
Previous CloseN/A
Volume0.00
Average Volume (3M)81.00
Market Cap
€214.08M
Enterprise Value€206.27M
Total Cash (Recent Filing)€18.41M
Total Debt (Recent Filing)€21.76M
Price to Earnings (P/E)―
Beta-0.20
Next Earnings
Oct 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding37,655,190
10 Day Avg. Volume223
30 Day Avg. Volume81
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.95
Price to Sales (P/S)7.45
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.49
Revenue Forecast (FY)€26.53M
Bulls Say, Bears Say
Bulls Say
Specialized AI Imaging FocusMedian's core expertise in medical imaging and AI creates durable competitive advantages: specialized algorithms, validated biomarkers and domain knowledge are high‑friction to replicate, help win trial work, and support long lead‑time client relationships with biopharma sponsors over multiple programs.
Improving Revenue TrajectoryA 21.5% revenue improvement in 2025 indicates accelerating commercial traction and increasing trial engagements. Sustained top‑line growth suggests the company can scale service delivery and platform adoption, providing a basis to invest in product refinement and capture larger, multi‑year contracts with sponsors.
Diversified Imaging Revenue Model & Structural TailwindsMultiple revenue levers—per‑trial services, software/platform licensing and partner collaborations—reduce reliance on any single contract type. Coupled with structural industry adoption of quantitative imaging biomarkers and AI endpoints, this mix supports recurring engagement opportunities and long‑term demand stability.
Bears Say
Negative Shareholders' EquityPersistent negative equity erodes financial flexibility and signals cumulative losses that reduce the company's ability to absorb shocks. It complicates borrowing, can force dilutive capital raises, and weakens creditor and partner negotiating positions—structural constraints on long‑term strategic options.
Chronic Cash BurnRepeated negative operating cash flow and negative free cash flow show reliance on external financing to fund operations. Over months this raises dilution and refinancing risk, limits reinvestment capacity into product development or sales expansion, and constrains the company’s ability to capitalize on new trial opportunities.
Deep Losses; Weak Gross MarginsSevere negative margins and a sharply negative gross profit point to structural cost or pricing problems that undermine scalability. Even with revenue growth, unprofitable unit economics require substantive business model fixes—cost reduction, pricing changes, or higher‑margin product adoption—to achieve sustainable profitability.
Median Technologies News
4ZG FAQ
What was Median Technologies’s price range in the past 12 months?
Median Technologies lowest stock price was €1.24 and its highest was €6.42 in the past 12 months.
What is Median Technologies’s market cap?
Median Technologies’s market cap is €214.08M.
When is Median Technologies’s upcoming earnings report date?
Median Technologies’s upcoming earnings report date is Oct 15, 2026 which is in 144 days.
How were Median Technologies’s earnings last quarter?
Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.677.
Is Median Technologies overvalued?
According to Wall Street analysts Median Technologies’s price is currently Overvalued.
Does Median Technologies pay dividends?
Median Technologies does not currently pay dividends.
What is Median Technologies’s EPS estimate?
Median Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Median Technologies have?
Median Technologies has 37,655,190 shares outstanding.
What happened to Median Technologies’s price movement after its last earnings report?
Median Technologies reported an EPS of -€0.677 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.212%.
Which hedge fund is a major shareholder of Median Technologies?
Currently, no hedge funds are holding shares in DE:4ZG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Median Technologies
Median Technologies SA develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iBiops, an end-to-end AI-powered technology software as a medical device that integrates and optimizes the entire medical imaging workflow; and iSee for image analysis services in clinical trials. It also provides imaging contract research services, such as study start up, image and clinical data management, scientific consulting, independent reviews, image data processing and site support, and study close-out for studies. Median Technologies SA has a research collaboration agreement with the University of California. The company was founded in 2002 and is based in Valbonne, France.